Ardea Biosciences Sells 4.025 Million Common Shares
April 12, 2010 (FinancialWire) — Ardea Biosciences, Inc. (NASDAQ: RDEA) has completed a public offering of 4.025 million shares of its common stock, including 525,000 shares sold due to the full exercise of an overallotment option previously granted to the underwriters. Jefferies & Co. (NASDAQ: JEF) acted as sole book-running manager in the offering.
According to Ardea, all of the shares were offered by the company. The company saw net proceeds of around $77.1 million.
California-based Ardea is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus. Ardea was formerly known as IntraBiotics Pharmaceuticals and was incorporated in Delaware in 1994.
In December 2006, the firm acquired intellectual property and other assets related to several classes of small-molecule therapeutics for the treatment of HIV and cancer from Valeant Research & Development, Inc., or Valeant.
FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.
[hlmsmlh] [biomedphrm] [fnncngj]
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
